Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 9:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 3,713 matching trials from the live ClinicalTrials.gov search.
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Anniston, Alabama • Miami, Florida • Orlando, Florida + 2 more
Conditions
Type 2 Diabetes Mellitus (T2DM), Type 1 Diabetes Mellitus (T1DM), Hyperglycemia
Interventions
Libre 3 Plus Continuous Glucose Monitor, Dexcom G7 Continuous Glucose Monitor
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Diabete Type 2, Neuropathy, Painful
Interventions
INF® Therapy, NVIf
Other
Lead sponsor
Loma Linda University
Other
Eligibility
35 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Loma Linda, California
Conditions
Obesity, Bariatric Surgery, Morbid Obesity, Diabetes Mellitus Type 2, Diet Therapy
Interventions
Roux-en-Y Gastric Bypass, Caloric Restriction
Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
3
States / cities
Baltimore, Maryland • Bethesda, Maryland • Nashville, Tennessee
Recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacogenetics of Response to GLP1R Agonists

NCT05071898
Conditions
Obesity, Diabetes Type 2
Interventions
Semaglutide Pen Injector [Ozempic]
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

NCT02820298
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lakewood, Colorado
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin aspart, insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 28 more
Conditions
Diabetes Mellitus Type 2, Non-alcoholic Fatty Liver Disease, Obesity
Interventions
Amlexanox, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Type 2 Diabetes
Interventions
AZD1656, Glucagon
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Diabetes Mellitus, Type 2
Interventions
LY3457263, Placebo, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Anniston, Alabama • Anaheim, California • South Miami, Florida + 2 more
Not listed No phase listed Observational Accepts healthy volunteers

Role of Cardiometabolic Risk Factors in Childhood Bone Development

NCT02355717
Conditions
Obesity, Cardiovascular Disease, Type 2 Diabetes, Osteoporosis
Interventions
Observational Study
Other
Lead sponsor
Augusta University
Other
Eligibility
9 Years to 15 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Reducing Obesity and Type 2 Diabetes in High Risk Youth

NCT01560676
Conditions
Obesity, Type 2 Diabetes
Interventions
HEALTH[e]TEEN, HEALTH[e]TEEN + CST
Behavioral
Lead sponsor
Yale University
Other
Eligibility
13 Years to 18 Years
Enrollment
384 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 4
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Guntersville, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 29 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Tesaglitazar
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Completed Not applicable Interventional Results available

Pioglitazone on Pancreatic Steatosis and Bone Health

NCT00855010
Conditions
Obesity, Type 2 Diabetes
Interventions
pioglitazone, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Diabetes
Interventions
Nutralin
Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Conditions
Type 1 Diabetes
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational

TODAY Genetics Study

NCT00722397
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
2,654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 20 more
Conditions
Type 2 Diabetes
Interventions
Lapaquistat acetate and lipid-lowering therapy, Lipid-lowering therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Tucson, Arizona • Artesia, California • Jacksonville, Florida + 15 more
Conditions
Diabetes Mellitus Type 2
Interventions
aleglitazar+metformin, placebo+metformin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
22
States / cities
Chino, California • Hawaiian Gardens, California • Los Angeles, California + 19 more
Conditions
Asthma, Diabetes Mellitus
Interventions
Inhaled Insulin, Subcutaneous Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 77 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
86
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 64 more
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
145
States / cities
Sheffield, Alabama • Glendale, Arizona • Mesa, Arizona + 113 more
Conditions
Diabetes Mellitus Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Pioglitazone, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 72 more
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4

NCT00574340
Conditions
Type 2 Diabetes
Interventions
Hyperinsulinemic Hypoglycemic Clamp
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland